Welcome to our dedicated page for Coeptis Therapeutics Holdings SEC filings (Ticker: COEPW), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on Coeptis Therapeutics Holdings's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time EDGAR feed updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into Coeptis Therapeutics Holdings's regulatory disclosures and financial reporting.
The Vanguard Group filed an Amendment No. 1 to its Schedule 13G/A reporting for Coeptis Therapeutics Holdings Inc. The amendment states beneficial ownership of 0 shares (0%) of Common Stock as disclosed, and explains an internal realignment of Vanguard subsidiaries effective January 12, 2026.
Coeptis Therapeutics Holdings, Inc. files its annual report describing a small, development‑stage biopharmaceutical and technology company with no approved drugs, minimal revenue and a focus on cell therapies and AI‑driven marketing software. The biopharma division is advancing preclinical platforms including CD38‑GEAR‑NK, CD38‑Diagnostic, the SNAP‑CAR universal cell therapy platform and allogeneic NK programs licensed from Deverra.
In 2025 Coeptis recorded a net loss of $12,277,192, bringing its accumulated deficit to $109,953,728, and its auditors raise substantial doubt about its ability to continue as a going concern. The company reports only six employees and expects to continue incurring losses while it funds R&D and looks for partners.
Strategically, Coeptis acquired the NexGenAI Affiliates Network marketing automation platform and agreed in April 2025 to spin out its biotechnology assets to shareholders while merging with Z Squared, Inc., with closing expected in the second quarter of 2026. The company highlights significant regulatory, financing, competition and Nasdaq listing risks and operates as an emerging growth company using reduced reporting requirements.
Coeptis Therapeutics Holdings, Inc. Chief Financial Officer Brian Cogley increased his direct ownership of common stock through an option exercise and an equity grant. On February 11, 2026, he exercised stock options to acquire 10,000 shares of common stock at an exercise price of $10.56 per share, converting derivative securities into shares.
On the same date, he also received a grant of 12,500 shares of restricted stock in connection with an option exchange program, where previously granted underwater options were surrendered in exchange for restricted stock. Following these transactions, he directly beneficially owned 22,500 shares of common stock.
Coeptis Therapeutics Holdings, Inc. director Philippe Deschamps increased his direct common stock holdings through equity awards. On February 11, 2026, he acquired 5,700 shares of common stock by exercising stock options at $10.56 per share, classified as an exercise or conversion of a derivative security.
On the same date, he also received a grant of 3,250 shares of restricted stock at a stated price of $0. This restricted stock was issued in an option exchange program in which he surrendered underwater options in return for restricted shares. Following these transactions, he directly beneficially owned 8,950 shares of Coeptis common stock.
Coeptis Therapeutics Holdings director Chris Calise increased his holdings through an option exercise and a stock grant. On 02/11/2026 he acquired 5,700 shares of common stock by exercising stock options at $10.56 per share and received 3,250 shares of restricted stock for no cash cost in connection with an option exchange program. Following these transactions, he beneficially owns 368,741 shares of common stock, including 49,500 shares held by CJC Investment Trust and 47,106 shares issuable under currently exercisable warrants.
Coeptis Therapeutics Holdings CEO and President David Mehalick, a director and 10% owner, reported acquiring additional common stock on February 11, 2026. He exercised stock options to receive 148,875 shares of common stock at a weighted average exercise price of $7.05 per share.
On the same date, he also received a grant of 51,250 shares of restricted stock in an option exchange program, where previously underwater options were surrendered for stock. Following these transactions, Mehalick directly beneficially owns 330,192 shares of Coeptis common stock.
Cochran Christopher P. reported acquisition or exercise transactions in a Form 4 filing for COEP. The filing lists transactions totaling 8,950 shares at a weighted average price of $10.56 per share. Following the reported transactions, holdings were 8,950 shares.
Coeptis Therapeutics Holdings, Inc. director and VP of Operations Daniel Alexander Yerace reported acquiring common stock on February 11, 2026. He obtained 10,000 shares through the exercise of stock options at a weighted average price of $10.41 per share. He also received a grant of 20,000 restricted shares issued in connection with an option exchange program in which he surrendered underwater options for restricted stock. Following these transactions, he directly beneficially owned 70,531 shares of Coeptis common stock.
Coeptis Therapeutics Holdings, Inc. director Gene Salkind reported acquiring additional common stock on February 11, 2026. He exercised stock options for 5,700 shares at $10.56 per share and also received a grant of 3,250 restricted shares through an option exchange program.
After these transactions, Salkind beneficially owns 13,161 shares of Coeptis common stock directly. This total includes 4,211 shares held as JTWROS with Catherine Salkind, meaning they share beneficial ownership of that portion.
Coeptis Therapeutics Holdings, Inc. director Tara DeSilva reported acquiring additional common stock on February 11, 2026. She obtained 5,700 shares through the exercise of stock options at an exercise price of $10.56 per share, and separately received a grant of 3,250 restricted shares in connection with an option exchange program where underwater options were surrendered. Following these transactions, she directly holds 8,950 shares of Coeptis Therapeutics common stock.